Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Clinical Application of Ketamine Ointment in the Treatment of Sympathetically Maintained Pain

Author(s):  Crowley Kenton L, Flores John A, Hughes Christine N, Iacono Robert P

Issue:  Mar/Apr 1998 - Pain Management
View All Articles in Issue

Page(s):  122-127

Download in electronic PDF format for $65

Abstract:  The objective of this study was to determine the clinical efficacy of topical ketamine in relieving sympathetically maintained pain, including complex regional pain syndrome types I and II, involving the upper and/or lower extremities. In an open clinical pilot study of five referral patients diagnosed with sympathetically maintained pain who were unresponsive to conventional modalities, a single dose of topical ketamine was administered. Age, gender, duration or degree of disease and concurrent medication were not controlled. Ketamine was prepared for transdermal delivery in pluronic lethicin organogel (PLO) in calibrated applicators. Concentrations ranged from 10 to 150 mg/mL. Dosage ranged from 10 mg to 700 mg per single application. Each dosage was determined clinically based on location and surface area of involvement. Pain intensity was measured using a validated numeric analogue scale (NAS). Ketamine in PLO applied to the upper and/or lower extremities with sympathetically maintained pain resulted in significant pain reduction relative to pretreatment NAS of 65% to 100%. Initial response was within 20 seconds to three minutes, with NAS rating 15 minutes postapplication. No reported side effect occurred on patient follow-up at 24 and 48 hours. Single-dose, topical application of ketamine in PLO (patent pending) appears clinically effective in relieving sympathetically maintained pain of the extremities without apparent side effects. Further controlled studies are warranted to define patient selection, optimize dosage and validate the prominent analgesic effects obtained in this heretofore difficult- to-treat pain syndrome. This was an independent study in joint cooperation with representatives from the University of California at Irvine, Loma Linda University Medical Center and private practice.

Related Keywords: Lecithin, Organogel, Pluronic

Related Categories: DERMATOLOGY, PAIN MANAGEMENT

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP
Allen Loyd V Jr
May/Jun 2003
Pg. 180-183

Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Frankum James
, Ramsay Dale, Das Nandita G, Das Sudip K
Mar/Apr 2004
Pg. 101-105

Morphine Sulfate 50 mg/mL in Pluronic Lecithin Organogel
Allen Loyd V Jr
May/Jun 2009
Pg. 244

Oxycodone Hydrochloride 10 mg/mL in Pluronic Lecithin Organogel
Allen Loyd V Jr
May/Jun 2009
Pg. 245

Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Glisson James K
, Wood Rebecca L, Kyle Patrick B, Cleary John D
May/Jun 2005
Pg. 242-246

The Use of Pluronic Lecithin Organogels in the Transdermal Delivery of Drugs
Bramwell Bethany L
, Williams LaVonn A
Jan/Feb 2012
Pg. 62-63

In Vitro Percutaneous Absorption of Ketoprofen and Testosterone: Comparison of Pluronic Lecithin Organogel vs. Pentravan Cream
Lehman Paul A
, Raney Sam G
May/Jun 2012
Pg. 248-252

Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Boddu Sai HS
, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
May/Jun 2014
Pg. 256-261

BHR in PLO Gel (Benadryl, Haldol, and Reglan in Pluronic Lecithin Organogel)
Allen Loyd V Jr
Jul/Aug 2021
Pg. 322

Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji
, Sumanasekera Wasana, Le Uyen Minh
Jan/Feb 2022
Pg. 65-71

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions